SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the following upcoming virtual investor conferences:
- Truist Securities AI Symposium-Biotech & Tools Symposium on Tuesday, March 1; Applying the Power of AI to Synthetic Biology and Other Tools to Develop Therapeutics Panel at 9:00 a.m. Eastern Time.
- Cowen 42nd Annual Health Care Conference on Monday, March 7; fireside chat at 2:10 p.m. Eastern Time.
- Cowen 42nd Annual Health Care Conference on Monday, March 7; Synthetic Biology Enabling Technologies Panel at 10:30 a.m. Eastern Time.
The Cowen presentations will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the presentations will be archived for a period of 30 days following the conclusion of the live event.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.